Respiratory Innovation Centre
The invoX Respiratory Innovation Centre is dedicated to the development of innovative and generic drug-device combination products which use the Softhaler®, a next-generation soft-mist device, to deliver known active pharmaceutical ingredients (APIs), new chemical entities (NCEs) and biomolecules to the lung.
Our Focus on Respiratory Diseases
Across the world, respiratory diseases are a significant cause of illness and death. The number of people with chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), continues to rise. These illnesses present a massive and increasing burden on the cost of public health and significantly impact the quality of life for patients.
Whilst major developments have occurred in the treatment of patients with respiratory disease, there is an increasing unmet need for both novel treatments and high-quality, affordable generic versions of inhaled products that have an established safety and efficacy profile. Our respiratory team is committed and passionate about delivering both.
Softhaler®, Soft-Mist Inhaler technology
Our respiratory team has developed a next-generation, proprietary soft-mist inhalation platform device, the Softhaler®, which uses differentiated technology to deliver propellant-free liquid-based formulations to the lung.
Our technology has a greener footprint than traditional inhalers due to simpler, typically water-based formulations which require a less intensive manufacturing process and contain no propellants or other volatile chemicals of environmental concern.
The Softhaler® device mechanically converts the liquid formulation into an ultra-fine mist to deliver the medication to the lungs more effectively than other types of inhalers, leading to better lung delivery and less deposition in the mouth or at the back of the throat.
Both smaller chemical API molecules and larger complex molecules can be delivered by the Softhaler® device. This leads to a wide variety of applications in generic products, as well as new combinations of existing APIs, NCEs and biologics, making the Softhaler® a true platform device.
Our Respiratory Team
The respiratory team is made up of a multicultural international group of highly experienced individuals with backgrounds in respiratory and device technology. All our team members have a mutual passion for developing and bringing to the market new respiratory products that can help improve the lives of patients.
Our highly skilled multidisciplinary team is experienced across all stages of product development from early concept and feasibility assessment through to late-phase drug product performance evaluation, technical transfers, submissions and commercialisation.
The R&D team are supported by industry experts from our corporate functions, such as Procurement, Supply Chain Management, Quality and Regulatory Affairs. Collectively, we are a world-class respiratory innovation team.
The invoX Respiratory Innovation Centre is located in Diepenbeek, Belgium. It was formed from the acquisition of Softhale N.V., a Belgian-based respiratory company, in March 2021.
Click here to learn more about our journey.
Bioville – Abis Building
Office tel. +32 11 28 69 91